Zuoli Pharmaceutical (300181.SZ): Linglianhua Granules Receive Approval for Clinical Trials

Zhitong Finance APP reported that Zuo Li Pharmaceutical (300181.SZ) announced that it has recently received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration (referred to as "NMPA"), approving the clinical trial research for the additional functional indications of its marketed product Linglianhua Granules. After review, the clinical trial application for Linglianhua Granules, accepted on June 1, 2026, meets the relevant requirements for drug registration. Based on further improvement of the clinical trial plan, the approval is granted for conducting clinical trials for the treatment of menopausal syndrome accompanied by anxiety and the condition of heart-kidney disharmony.